BCM
Burrage Capital Management Portfolio holdings
AUM
$99.7M
This Quarter Return
+51.19%
1 Year Return
+65.92%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$143M
AUM Growth
+$143M
(+41%)
Cap. Flow
+$2.17M
Cap. Flow
% of AUM
1.52%
Top 10 Holdings %
Top 10 Hldgs %
59.86%
Holding
34
New
3
Increased
4
Reduced
11
Closed
8
Top Buys
| 1 |
ADC Therapeutics
ADCT
|
$6.32M |
| 2 |
Fulcrum Therapeutics
FULC
|
$5.33M |
| 3 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$3.68M |
| 4 |
Insmed
INSM
|
$2.75M |
| 5 |
Merus
MRUS
|
$2.26M |
Top Sells
| 1 |
CytomX Therapeutics
CTMX
|
$3.46M |
| 2 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$3.29M |
| 3 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$2.78M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$2.11M |
| 5 |
Y-mAbs Therapeutics
YMAB
|
$2.11M |
Sector Composition
| 1 | Healthcare | 96.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EPZM
1
DELISTED
Epizyme, Inc
EPZM
| $14.3M | 10.02% | 891,277 -2,421 | -0.3% | -$38.9K |
|
2
MEI Pharma
MEIP
$160M
| $12.4M | 8.67% | 3,001,150 -16,909 | -0.6% | -$69.8K |
|
3
PTC Therapeutics
PTCT
$3.92B
| $9.1M | 6.37% | 179,386 -1,851 | -1% | -$93.9K |
|
|
GTHX
4
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $9.07M | 6.35% | 373,876 -4,269 | -1% | -$104K |
|
|
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $7.53M | 5.27% | 1,476,871 -44,511 | -3% | -$227K |
|
6
OrthoPediatrics
KIDS
$536M
| $7.42M | 5.19% | 169,468 -1,645 | -1% | -$72K |
|
7
AnaptysBio
ANAB
$569M
| $7.33M | 5.13% | 328,114 -3,805 | -1% | -$85K |
|
|
8
ADC Therapeutics
ADCT
$345M
| $6.32M | 4.42% | +134,912 | New | +$6.32M |
|
9
Cytokinetics
CYTK
$4.23B
| $6.16M | 4.31% | 261,491 -56,782 | -18% | -$1.34M |
|
10
NeoGenomics
NEO
$1.13B
| $5.89M | 4.12% | 190,205 -2,072 | -1% | -$64.2K |
|
|
AIMT
11
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $5.56M | 3.89% | 332,546 +220,000 | +195% | +$3.68M |
|
|
12
Fulcrum Therapeutics
FULC
$351M
| $5.33M | 3.73% | +291,645 | New | +$5.33M |
|
|
13
Y-mAbs Therapeutics
YMAB
$388M
| $5.32M | 3.72% | 123,025 -48,763 | -28% | -$2.11M |
|
|
TPTX
14
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $4.99M | 3.49% | 77,172 | – | – |
|
15
Korro Bio
KRRO
$217M
| $4.74M | 3.32% | 203,917 +30,000 | +17% | +$697K |
|
|
16
Insmed
INSM
$28.8B
| $4.56M | 3.19% | 165,400 +100,000 | +153% | +$2.75M |
|
17
Regenxbio
RGNX
$451M
| $4.24M | 2.96% | 115,000 | – | – |
|
18
Aurinia Pharmaceuticals
AUPH
$1.58B
| $4.17M | 2.92% | 256,438 +60,000 | +31% | +$975K |
|
19
Crinetics Pharmaceuticals
CRNX
$2.92B
| $4.14M | 2.9% | 236,394 -45,878 | -16% | -$804K |
|
|
TECX
20
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $3.94M | 2.76% | 225,900 | – | – |
|
21
Adverum Biotechnologies
ADVM
$64.6M
| $3.26M | 2.28% | 156,012 | – | – |
|
22
Apellis Pharmaceuticals
APLS
$3.48B
| $2.43M | 1.7% | 74,452 | – | – |
|
|
23
Merus
MRUS
$4.98B
| $2.26M | 1.58% | +140,176 | New | +$2.26M |
|
|
ZGNX
24
DELISTED
Zogenix, Inc.
ZGNX
| $1.89M | 1.32% | 70,000 | – | – |
|
|
KDNY
25
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $314K | 0.22% | 135,898 | – | – |
|